- Sarepta Therapeutics Announces Advisory Committee Meeting will be Held for SRP-9001
- Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Recent Corporate Developments
- Sarepta Therapeutics Announces Call for Applications for the 6th Annual Route 79, The Duchenne Scholarship Program
- Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2022 Financial Results
- Sarepta Therapeutics Announces Initiation of VOYAGENE, a Clinical Study of SRP-9003 for the Treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4
- Sarepta and Catalent Expand Strategic Manufacturing Partnership With Commercial Supply Agreement for Duchenne Muscular Dystrophy Gene Therapy Candidate
Sarepta Therapeutics Inc (0L35:LSE) closed at 136.74, -14.41% below its 52-week high of 159.77, set on Mar 06, 2023.
64.39May 10 2022159.77Mar 06 2023
Short selling activityProvided by S&P Global Market Intelligence
|Market cap||11.97bn USD|
|EPS (TTM)||-8.03 |
Data delayed at least 20 minutes, as of Mar 29 2023 17:30 BST.